Compare IBRX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | CRL |
|---|---|---|
| Founded | 2014 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.5B |
| IPO Year | 2015 | 1999 |
| Metric | IBRX | CRL |
|---|---|---|
| Price | $7.59 | $171.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $12.57 | ★ $200.09 |
| AVG Volume (30 Days) | ★ 24.1M | 718.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $113,288,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | $88.59 | $0.99 |
| Revenue Next Year | $131.15 | $3.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 668.31 | 10.48 |
| 52 Week Low | $1.83 | $91.86 |
| 52 Week High | $12.43 | $228.88 |
| Indicator | IBRX | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 54.49 |
| Support Level | $2.25 | $146.49 |
| Resistance Level | $8.28 | $182.76 |
| Average True Range (ATR) | 0.93 | 7.21 |
| MACD | -0.24 | 2.02 |
| Stochastic Oscillator | 39.00 | 99.98 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.